Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.2% - Should You Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price traded down 1.2% on Thursday . The company traded as low as $66.36 and last traded at $67.40. 3,202,078 shares were traded during trading, a decline of 66% from the average session volume of 9,443,552 shares. The stock had previously closed at $68.20.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

The company has a market capitalization of $306.54 billion, a PE ratio of 20.74, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The firm's 50-day moving average is $66.82 and its 200-day moving average is $83.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of NVO. M. Kulyk & Associates LLC grew its position in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after buying an additional 119 shares during the period. Center for Financial Planning Inc. raised its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the period. Tradewinds Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after acquiring an additional 124 shares in the last quarter. Exencial Wealth Advisors LLC increased its holdings in Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after acquiring an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC lifted its position in Novo Nordisk A/S by 4.2% during the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after purchasing an additional 126 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.